Moragon Santiago, Hernando Cristina, Martinez-Martinez Maria Teresa, Tapia Marta, Ortega-Morillo Belen, Lluch Ana, Bermejo Begoña, Cejalvo Juan Miguel
Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, 46010 Valencia, Spain.
Instituto de Salud Carlos III, CIBERONC (Centro De Investigacion Biomedica En Red De Cancer), 28220 Madrid, Spain.
Cancers (Basel). 2022 Jun 28;14(13):3167. doi: 10.3390/cancers14133167.
Understanding the biological aspects of immune response in HER2+ breast cancer is crucial to implementing new treatment strategies in these patients. It is well known that anti-HER2 therapy has improved survival in this population, yet a substantial percentage may relapse, creating a need within the scientific community to uncover resistance mechanisms and determine how to overcome them. This systematic review indicates the immunological mechanisms through which trastuzumab and other agents target cancer cells, also outlining the main trials studying immune checkpoint blockade. Finally, we report on anti-HER2 vaccines and include a figure exemplifying their mechanisms of action.
了解HER2阳性乳腺癌免疫反应的生物学方面对于在这些患者中实施新的治疗策略至关重要。众所周知，抗HER2治疗已改善了这一人群的生存率，但仍有相当比例的患者可能复发，这促使科学界有必要揭示耐药机制并确定如何克服这些机制。本系统综述指出了曲妥珠单抗和其他药物靶向癌细胞的免疫机制，还概述了研究免疫检查点阻断的主要试验。最后，我们报告了抗HER2疫苗，并提供了一个说明其作用机制的图表。
